efficacy and safety of switching from sitagliptin to

efficacy and safety of switching from sitagliptin to
News

2.3.2 Safety

Liraglutide Liraglutide Sitagliptin Sitagliptin N (%) E N (%) E Number of subjects 202 (100) 204 (100) Total AEs 139 (68.8) 455 116 (56.9) 318 Serious AEs 6 (3.0) 8 7 (3.4) 8
18 more rows ... Sep 30 2021Cited by: 21Publish Year: 2016sp.info Efficacy and safety of switching from sitagliptin to ...Conclusions: Subjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.Cited by: 21Publish Year: 2016Author: Timothy S. Bailey, Róbert Takács, Francisco J. Tinahones, Paturi V. Rao, George M. Tsoukas, Anne Blo...sp.info Efficacy and Safety of Switching From Sitagliptin to ...Jul 25, 2013 · This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control onActual Enrollment : 407 participantsIntervention Model: Parallel AssignmentAllocation: RandomizedStudy Type : Interventional (Clinical Trial)sp.info Efficacy and safety of switching from the DPP-4 inhibitor ...Glycemic control, weight, and treatment satisfaction improved after switching from sitagliptin to liraglutide, albeit with a transient increase in gastrointestinal reactions. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trialCited by: 79Publish Year: 2012Author: Richard E. Pratley, Michael A. Nauck, Timothy Bailey, Eduard Montanya, Sebastiano Filetti, Alan J. G...

Efficacy and safety of switching from sitagliptin to ...

22 rows · Jul 06, 2016 · Subjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain ...Cited by: 21Publish Year: 2016Author: Timothy S. Bailey, Róbert Takács, Francisco J. Tinahones, Paturi V. Rao, George M. Tsoukas, Anne Blo... N (%) E N (%) E - Number of subjects 202 (100) - 204 (100) - Total AEs 139 (68.8) 455 116 (56.9) 318 Serious AEs 6 (3.0) 8 7 (3.4) 8 See all 22 rows on dom-pubs.onlinelibrary.wiley.comsp.info Efficacy and safety of switching from basal insulin to ...We assessed the efficacy and safety of replacing basal insulin by sitagliptin therapy in Japanese type 2 diabetes patients on BOT. Forty-nine subjects were sequentially recruited for the 52-week, prospective, single arm study. Patients on BOT therapy were switched from basal insulin to sitagliptin. The primary endpoint was change in HbA1c in 52 weeks.Cited by: 2Publish Year: 2012Author: S.-I. Harashima, D. Tanaka, S. Yamane, M. Ogura, Y. Fujita, Y. Murata, M. Seike, T. Koizumi, M. Aono...sp.info (PDF) Efficacy and safety of switching from sitagliptin to ...Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH™): a randomized, double-blind, double …Estimated Reading Time: 6 minssp.info Efficacy and Safety of Switching From the DPP-4 Inhibitor ...Oct 01, 2012 · For participants switching from sitagliptin to liraglutide (weeks 52–78), efficacy and safety were analyzed with the extension analysis set, all full analysis set 52-week completers exposed to the trial products during the extension.Cited by: 79Publish Year: 2012Author: Richard E. Pratley, Michael A. Nauck, Timothy Bailey, Eduard Montanya, Sebastiano Filetti, Alan J. G...Estimated Reading Time: 9 mins

Efficacy and safety of switching from sitagliptin to ...

Sep 14, 2016 · Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double …Cited by: 21Publish Year: 2016Author: Timothy S. Bailey, Róbert Takács, Francisco J. Tinahones, Paturi V. Rao, George M. Tsoukas, Anne Blo...sp.info DURATION-2: efficacy and safety of switching from …Patients who switched to once-weekly exenatide from daily sitagliptin or pioglitazone had improved or sustained glycaemic control, with weight loss. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatideCited by: 147Publish Year: 2011Author: C. Wysham, R. Bergenstal, J. Malloy, P. Yan, B. Walsh, J. Malone, K. Taylorsp.info ficacy and safety of switching from sitagliptin to ...Conclusions: Subjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety.sp.info DURATION‐2: efficacy and safety of switching from …Significantly more patients achieved fasting plasma glucose ≤ 7 mmol/l after switching from sitagliptin to exenatide once‐weekly (week 26 → week 52: 38% → 58%; P = 0.0002). Body weight Patients who switched from pioglitazone to exenatide once‐weekly exhibited a significant weight reduction (−3.0 kg; P < 0.0001; Fig. 3 ), such that body weight was similar to original …Cited by: 147Publish Year: 2011Author: C. Wysham, R. Bergenstal, J. Malloy, P. Yan, B. Walsh, J. Malone, K. Taylor

Efficacy and Safety of Switching From Sitagliptin to ...

Jul 25, 2013 · Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin (LIRA-SWITCH™) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.Conditions: DiabetesDiabetes Mellitus, Type 2Enrollment: 407sp.info Long-term efficacy and safety of oral semaglutide and the ...Switching from sitagliptin to flexibly dosed oral semaglutide maintained HbA 1c reductions, helped more patients achieve HbA 1c targets with less use of additional glucose-lowering medication, and offers the potential for additional reductions in …Cited by: 3Publish Year: 2020Author: John B Buse, Bruce W Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Morten A...sp.info Long-term efficacy and safety of oral semaglutide and the ...The extension phase of PIONEER 7, reported here, had two aims: to evaluate the long-term efficacy and safety of oral semaglutide with flexible dose adjustment; and to evaluate the efficacy and safety when switching from sitagliptin to oral semaglutide with flexible dose adjustment compared with continued sitagliptin.Cited by: 3Publish Year: 2020Author: John B Buse, Bruce W Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Morten A...sp.info Long-term efficacy and safety of oral semaglutide and …well tolerated with no new safety signals. Switching from sitagliptin to oral semaglutide with flexible dose adjustment maintained glycated hemo-globin (HbA 1c) reductions with less need for additional glucose-lowering medications, improved the likeli-hood of achieving an HbA 1c target of <7.0%, and may provide additional reductions in body weight.Cited by: 3Publish Year: 2020Author: John B Buse, Bruce W Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Morten A...

Efficacy and safety of the addition of sitagliptin to ...

Nov 14, 2021 · To assess the efficacy and safety of sitagliptin in youth with type 2 diabetes (T2D) inadequately controlled with metformin ± insulin. Study Design Data were pooled from two 54-week, double-blind, randomized, placebo-controlled studies of sitagliptin 100 mg daily or placebo added onto treatment of 10- to 17-year-old youth with T2D and ...sp.info Long-term efficacy and safety of oral semaglutide and the ...Dec 01, 2020 · The extension phase of PIONEER 7, reported here, had two aims: to evaluate the long-term efficacy and safety of oral semaglutide with flexible dose adjustment; and to evaluate the efficacy and safety when switching from sitagliptin to oral semaglutide with flexible dose adjustment compared with continued sitagliptin.Cited by: 3Publish Year: 2020Author: John B Buse, Bruce W Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Morten A...Estimated Reading Time: 13 minssp.info Efficacy and Safety of Dulaglutide Versus Sitagliptin ...Jul 12, 2014 · Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care 2012; 35:1986–1993 [PMC free …Cited by: 281Publish Year: 2014Author: Michael Nauck, Ruth S. Weinstock, Guillermo E. Umpierrez, Bruno Guerci, Zachary Skrivanek, Zvonko Mi...sp.info DURATION‐2: efficacy and safety of switching from …Mar 22, 2011 · This subsequent, 26‐week, open‐label, uncontrolled assessment period evaluated the safety and efficacy of (i) continued exenatide once‐weekly treatment and (ii) switching from sitagliptin or pioglitazone to exenatide once‐weekly. Methods Randomised oral medications were discontinued and all patients received exenatide once‐weekly.Cited by: 147Publish Year: 2011Author: C. Wysham, R. Bergenstal, J. Malloy, P. Yan, B. Walsh, J. Malone, K. Taylor

Efficacy and safety of sitagliptin in Japanese patients ...

Sep 24, 2013 · In the present study, we examined the efficacy and safety of switching patients with type 2 diabetes from glinides to sitagliptin, in comparison with continuous glinide treatment. Indicators of glycemic control and meal tolerance tests were used to compare the efficacy of these antidiabetic agents.Cited by: 2Publish Year: 2014Author: Tsuyoshi Tanaka, Hiroyuki Goto, Rika Araki, Mika Yamamoto, Takashi Tanaka, Ryoko Fujiwara, Kazuya Mu...sp.info Efficacy and Safety of Dulaglutide Versus Sitagliptin ...Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care 2012; 35: 1986 – 1993 pmid: 22851600sp.info Efficacy and safety of switching from the DPP-4 inhibitor ...Jul 30, 2012 · To assess the efficacy and safety of switching from sitagliptin to liraglutide in metformin-treated adults with type 2 diabetes. Research design and methods In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.Cited by: 79Publish Year: 2012Author: Richard E. Pratley, Michael A. Nauck, Timothy Bailey, Eduard Montanya, Sebastiano Filetti, Alan J. G...sp.info Efficacy and safety of sitagliptin in elderly patients ...Jul 28, 2017 · Purpose To determine the efficacy and safety of sitagliptin when used with some therapeutic drugs to treat elderly patients. Methods Sitagliptin (50 mg/day) was added to the pre-existing therapy for type 2 diabetes. Changes in the glycated hemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline, and exploratory analysis was …Cited by: 1Publish Year: 2017Author: Noriko Ujihara, Hiroshi Sakura, Naotake Hashimoto, Kazuo Sasamoto, Hiroshi Ohashi, Sumiko Hasumi, Ta...

Efficacy and Safety of Switching to Teneligliptin in ...

May 11, 2019 · The aim of this study was to evaluate the efficacy and safety of switching therapy to teneligliptin in patients with T2DM who had inadequate glycemic control despite treatment with a stable dose of other DPP-4 inhibitors. This study has been planned to follow up participants from baseline to 52 weeks after enrollment, and it is ongoing.Cited by: 3Publish Year: 2019Author: Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon Gi Choi, Hyuk Jae Chang, Soo Kyoung Kim, Jae Myung ...sp.info Efficacy and safety of sitagliptin in Japanese patients ...Sep 24, 2013 · In the present study, we examined the efficacy and safety of switching patients with type 2 diabetes from glinides to sitagliptin, in comparison with continuous glinide treatment. Indicators of glycemic control and meal tolerance tests were used to compare the efficacy of these antidiabetic agents.Cited by: 2Publish Year: 2014Author: Tsuyoshi Tanaka, Hiroyuki Goto, Rika Araki, Mika Yamamoto, Takashi Tanaka, Ryoko Fujiwara, Kazuya Mu...sp.info Long-term efficacy and safety of oral semaglutide and the ...Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: A 52-week, randomized, open-label extension of the PIONEER 7 trialCited by: 3Publish Year: 2020Author: John B Buse, Bruce W Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Morten A...sp.info Efficacy and Safety of Switching to Teneligliptin in ...Sep 18, 2021 · Introduction The aim of this study was to assess the efficacy and safety of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM) inadequately controlled despite treatment with a stable dose of other DPP-4 inhibitors. Methods Patients with glycosylated hemoglobin (HbA1c) ≥ 7% despite taking …Author: Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon Gi Choi, Hyuk Jae Chang, Soo Kyoung Kim, Jae Myung ...Publish Year: 2021Some results are removed in response to a notice of local law requirement. For more information, please see here.

Message

You may also leave contact information, we will contact you as soon as possible!